Description:

Anti-VEGF therapy has revolutionized the treatment of exudative retinal vascular disease. Whereas the first generations of anti-VEGF therapy hoped to improve quality of life through vision maintenance and remediation, newer advancement hope to decrease the burden of treatment while providing comparable visual outcomes. This course will briefly review current paradigms of anti-VEGF therapy before delving into novel anti-VEGF delivery systems and agents.

Course Code:

AOA344-TD

Speaker(s):

Daniel Epshtein, O.D.

daniel.epshtein.od@gmail.com

Credits:

1

AOA Expiration Date:

12/2/2025

Related News

Ask the Coding Experts

You ask, the experts answer. The AOA Coding and Reimbursement Committee supports the AOA's strategic direction to develop and value procedural (CPT), diagnostic (ICD-10) and supply codes (HCPCS). Members can submit questions regarding medical records and coding to askthecodingexpert@aoa.org. Here are the latest questions.

AOA on Capitol Hill 2025: Live News Updates

Welcome to the official news hub for AOA on Capitol Hill 2025! Follow along with the AOA's exclusive coverage from optometry's single-largest federal advocacy event in Washington, D.C., and learn about the issues 600 of our colleagues championed on Capitol Hill.

A global force: Highlights from Optometry's Meeting® | 5th World Congress of Optometry

Check out what you might have missed at Optometry's Meeting® 2025!